Preliminary data from a clinical trial led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) showed that Gilead Sciences’ remdesivir led to faster recovery in Covid-19 patients.
The ACTT trial, which involved 1063 hospitalised patients with advanced Covid-19 and lung involvement, compared the experimental antiviral drug to placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Results showed a 31% faster time to recovery in patients treated with Gilead’s drug versus placebo. The median time to recovery was 11 days versus 15 days, respectively.
